Get the Stockscreener App
2.53
4.12%
0.10
After Hours:
2.54
0.01
+0.40%
Esperion Therapeutics Inc stock is traded at $2.53, with a volume of 7.61M.
It is up +4.12% in the last 24 hours and up +69.80% over the past month.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
See More
Previous Close:
$2.43
Open:
$2.43
24h Volume:
7.61M
Relative Volume:
1.66
Market Cap:
$510.11M
Revenue:
$116.33M
Net Income/Loss:
$-209.25M
P/E Ratio:
-1.1934
EPS:
-2.12
Net Cash Flow:
$-135.49M
1W Performance:
+14.48%
1M Performance:
+69.80%
6M Performance:
+42.94%
1Y Performance:
+39.01%
1-Day Range:
$2.395
$2.58
1-Week Range:
$2.09
$2.58
52-Week Range:
$0.6925
$3.94
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Name
Esperion Therapeutics Inc
Sector
Phone
734-887-3903
Address
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Compare ESPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
2.53 | 467.76M | 116.33M | -209.25M | -135.49M | -2.12 |
|
ZTS
Zoetis Inc
|
153.20 | 67.75B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.29 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.84 | 43.70B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.48 | 21.51B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
380.47 | 18.31B | 2.99B | 1.21B | 1.13B | 25.06 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-24 | Initiated | Goldman | Neutral |
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-20-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Aug-01-23 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Jun-15-23 | Upgrade | BofA Securities | Underperform → Buy |
| Mar-16-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-16-23 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Mar-07-23 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-27-23 | Resumed | BofA Securities | Neutral |
| Feb-24-23 | Upgrade | Jefferies | Hold → Buy |
| Feb-03-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Aug-03-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| May-05-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-10-22 | Initiated | H.C. Wainwright | Buy |
| Oct-19-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Oct-14-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| May-05-21 | Downgrade | Stifel | Buy → Hold |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-11-21 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-12-21 | Downgrade | Jefferies | Buy → Hold |
| Feb-09-21 | Downgrade | Goldman | Neutral → Sell |
| Jan-15-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-10-20 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-29-20 | Resumed | JP Morgan | Underweight |
| Aug-11-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Apr-01-20 | Resumed | BofA/Merrill | Buy |
| Mar-17-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-24-20 | Downgrade | Northland Capital | Outperform → Market Perform |
| Feb-14-20 | Downgrade | Citigroup | Buy → Neutral |
| Sep-16-19 | Upgrade | Goldman | Sell → Neutral |
| May-29-19 | Downgrade | Goldman | Neutral → Sell |
| May-06-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Apr-26-19 | Upgrade | Goldman | Sell → Neutral |
| Mar-13-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-07-19 | Reiterated | Needham | Strong Buy |
| Dec-13-18 | Initiated | Goldman | Sell |
| Oct-29-18 | Upgrade | Northland Capital | Market Perform → Outperform |
| Oct-16-18 | Initiated | BTIG Research | Buy |
| Aug-17-18 | Upgrade | Citigroup | Neutral → Buy |
| Jul-11-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-03-18 | Downgrade | JP Morgan | Neutral → Underweight |
| May-02-18 | Downgrade | BofA/Merrill | Buy → Underperform |
View All
Esperion Therapeutics Inc Stock (ESPR) Latest News
Is this a good reentry point in Esperion Therapeutics Inc.Market Activity Recap & Proven Capital Preservation Tips - Newser
Market reaction to Esperion Therapeutics Inc.’s recent newsShare Buyback & AI Enhanced Market Trend Forecasts - Newser
Combining machine learning predictions for Esperion Therapeutics Inc.July 2025 Outlook & Daily Volume Surge Signals - Newser
Esperion Therapeutics Inc. stock chart pattern explained2025 Bull vs Bear & High Return Trade Opportunity Guides - Newser
Real time pattern detection on Esperion Therapeutics Inc. stockPortfolio Value Summary & Growth Focused Stock Pick Reports - Newser
Will Esperion Therapeutics Inc. benefit from macro trendsJuly 2025 Institutional & Intraday High Probability Alerts - Newser
Tools to monitor Esperion Therapeutics Inc. recovery probabilityJuly 2025 Reactions & Fast Exit/Entry Strategy Plans - Newser
Published on: 2025-09-03 04:01:00 - Newser
Technical analysis overview for Esperion Therapeutics Inc. stockWeekly Trade Summary & Weekly High Return Forecasts - Newser
Candlestick signals on Esperion Therapeutics Inc. stock todayWeekly Trend Summary & AI Forecasted Stock Moves - Newser
What institutional flow reveals about Esperion Therapeutics Inc.Wall Street Watch & Safe Swing Trade Setups - Newser
Is Esperion Therapeutics Inc. benefiting from innovation trendsQuarterly Profit Review & AI Powered Buy/Sell Recommendations - khodrobank.com
Using flow based indicators on Esperion Therapeutics Inc.2025 Momentum Check & Expert Curated Trade Ideas - Newser
Using Bollinger Bands to evaluate Esperion Therapeutics Inc.Quarterly Risk Review & Safe Capital Growth Stock Tips - Newser
Published on: 2025-09-02 13:26:49 - Newser
Is Esperion Therapeutics Inc. stock ready for a breakout2025 EndofYear Setup & Accurate Entry and Exit Point Alerts - Newser
Can Esperion Therapeutics Inc. keep up with sector leadersOil Prices & Weekly Setup with High ROI Potential - khodrobank.com
Movement Recap: Can Esperion Therapeutics Inc. scale operations efficientlyGap Down & Real-Time Chart Pattern Alerts - khodrobank.com
Esperion rises after revenue beat, Q1 profitability expectation - MSN
Using data tools to time your Esperion Therapeutics Inc. exit2025 Institutional Moves & Accurate Trade Setup Notifications - Newser
Published on: 2025-09-01 19:45:56 - Newser
Is Esperion Therapeutics Inc. forming a bullish divergenceJuly 2025 Institutional & Pattern Based Trade Signal System - khodrobank.com
Should you hold or exit Esperion Therapeutics Inc. nowJuly 2025 Reactions & Free Growth Oriented Trading Recommendations - Newser
Analyzing Esperion Therapeutics Inc. with risk reward ratio chartsProduct Launch & Fast Entry Momentum Alerts - Newser
Published on: 2025-09-01 01:32:54 - Newser
Chart based analysis of Esperion Therapeutics Inc. trendsIndex Update & Fast Momentum Entry Tips - Newser
Using data models to predict Esperion Therapeutics Inc. stock movement2025 Valuation Update & AI Powered Market Trend Analysis - Newser
Heatmap analysis for Esperion Therapeutics Inc. and competitorsEarnings Overview Report & Safe Investment Capital Preservation Plans - Newser
Signal strength of Esperion Therapeutics Inc. stock in tech scannersMarket Growth Report & Fast Momentum Entry Tips - Newser
Will a bounce in Esperion Therapeutics Inc. offer an exitWeekly Loss Report & Risk Adjusted Swing Trade Ideas - Newser
Understanding Esperion Therapeutics Inc.’s price movementJuly 2025 Decliners & Momentum Based Trading Signals - Newser
Reversal indicators forming on Esperion Therapeutics Inc. stockMarket Sentiment Review & Growth Focused Investment Plans - Newser
Esperion Therapeutics Inc. stock trendline breakdownWeekly Trend Recap & Smart Money Movement Tracker - Newser
Analyzing recovery setups for Esperion Therapeutics Inc. investorsOil Prices & Growth Focused Stock Reports - Newser
Esperion Therapeutics Inc Stock (ESPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Esperion Therapeutics Inc Stock (ESPR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Halladay Benjamin | Chief Financial Officer |
Jul 17 '25 |
Sale |
1.11 |
11 |
12 |
474,462 |
3.60%
0.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):